Crescita Therapeutics Inc banner

Crescita Therapeutics Inc
TSX:CTX

Watchlist Manager
Crescita Therapeutics Inc Logo
Crescita Therapeutics Inc
TSX:CTX
Watchlist
Price: 0.5 CAD -3.85%
Market Cap: CA$9.3m

Relative Value

CTX doesn't have a meaningful market cap.

The Relative Value of one CTX stock under the Base Case scenario is 0.59 CAD. Compared to the current market price of 0.5 CAD, Crescita Therapeutics Inc is Undervalued by 16%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CTX Relative Value
Base Case
0.59 CAD
Undervaluation 16%
Relative Value
Price
Worst Case
Base Case
Best Case

Multiples Across Competitors

CTX Competitors Multiples
Crescita Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Crescita Therapeutics Inc
TSX:CTX
9.3m CAD 0.4 20.4 1.8 -1.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 15.3 48.4 32.6 34.7
US
Johnson & Johnson
NYSE:JNJ
574.1B USD 6.1 21.4 14.9 18.3
CH
Roche Holding AG
SIX:ROG
283.4B CHF 4.6 30 12.7 14.8
US
Merck & Co Inc
NYSE:MRK
296.9B USD 4.5 16 10 11.7
CH
Novartis AG
SIX:NOVN
231.1B CHF 5.3 21.2 13.1 16.8
UK
AstraZeneca PLC
LSE:AZN
216.8B GBP 5.1 31.7 15.1 22.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.6 13.8 10.1 11.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Pfizer Inc
NYSE:PFE
154B USD 2.4 19.7 7.4 9.8
US
Bristol-Myers Squibb Co
NYSE:BMY
124B USD 2.6 17.7 6.9 8.9
P/E Multiple
Earnings Growth PEG
CA
Crescita Therapeutics Inc
TSX:CTX
Average P/E: 24
20.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.4
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.4
7%
3.1
CH
Roche Holding AG
SIX:ROG
30
29%
1
US
Merck & Co Inc
NYSE:MRK
16
14%
1.1
CH
Novartis AG
SIX:NOVN
21.2
15%
1.4
UK
AstraZeneca PLC
LSE:AZN
31.7
38%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
13.8
7%
2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
19.7
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.7
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Crescita Therapeutics Inc
TSX:CTX
Average EV/EBITDA: 41.6
1.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.6
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
14.9
2%
7.5
CH
Roche Holding AG
SIX:ROG
12.7
5%
2.5
US
Merck & Co Inc
NYSE:MRK
10
7%
1.4
CH
Novartis AG
SIX:NOVN
13.1
9%
1.5
UK
AstraZeneca PLC
LSE:AZN
15.1
10%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
10.1
7%
1.4
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.9
-13%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Crescita Therapeutics Inc
TSX:CTX
Average EV/EBIT: 98.4
Negative Multiple: -1.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.7
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.3
6%
3
CH
Roche Holding AG
SIX:ROG
14.8
6%
2.5
US
Merck & Co Inc
NYSE:MRK
11.7
6%
2
CH
Novartis AG
SIX:NOVN
16.8
12%
1.4
UK
AstraZeneca PLC
LSE:AZN
22.2
23%
1
DK
Novo Nordisk A/S
CSE:NOVO B
11.8
8%
1.5
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
9.8
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.9
-6%
N/A